ELDN ▲ +4.1% - Eledon Pharmaceuticals, Inc. $ELDN - Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society Eledon Pharmaceuticals rose 4.1% following the company's presentation of updated long-term data from its Phase 2 BESTOW extension study at the International Congress of The Transplantation Society. The positive clinical results appear to have boosted investor confidence in the company's transplant-focused pipeline. 22-SEP-2026 07:00 AM ET